Lack of association of the CIITA -168A→G promoter SNP with myasthenia gravis and its role in autoimmunity

8Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: The major histocompatibility complex class II transactivator (CIITA) regulates MHC class II gene expression. A promoter SNP -168A→G (rs3087456) has previously been shown to be associated with susceptibility to several immune mediated disorders, including rheumatoid arthritis (RA), multiple sclerosis (MS) and myocardial infarction (MI). Myasthenia gravis (MG) is an autoimmune disorder which has previously been shown to be associated with polymorphisms of several autoimmune predisposing genes, including IL-1, PTPN22, TNF-α and the MHC. In order to determine if allelic variants of rs3087456 increase predisposition to MG, we analyzed this SNP in our Swedish cohort of 446 MG patients and 1866 controls.Results: No significant association of the SNP with MG was detected, neither in the patient group as a whole, nor in any clinical subgroup. The vast majority of previous replication studies have also not found an association of the SNP with autoimmune disorders.Conclusions: We thus conclude that previous findings with regard to the role of the CIITA -168A→G SNP in autoimmunity may have to be reconsidered. © 2010 Ramanujam et al; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Ramanujam, R., Zhao, Y., Pirskanen, R., & Hammarström, L. (2010). Lack of association of the CIITA -168A→G promoter SNP with myasthenia gravis and its role in autoimmunity. BMC Medical Genetics, 11(1). https://doi.org/10.1186/1471-2350-11-147

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free